/CBLL
CBLL Stock - CeriBell, Inc.
Healthcare|Medical - DevicesNASDAQ
$21.20-0.70%
$0.15 (-0.70%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.5%upside
Target: $30.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CBLL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$20.99 – $21.41
TARGET (TP)$30.00
STOP LOSS$19.50
RISK/REWARD1:5.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.34
52W High$27.58
52W Low$10.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $65.44M | $45.23M | $25.92M |
| Gross Profit | $56.75M | $38.16M | $21.49M |
| Gross Margin | 86.7% | 84.4% | 82.9% |
| Operating Income | $-39,709,000 | $-30,041,000 | $-36,021,000 |
| Net Income | $-40,455,000 | $-29,464,000 | $-37,164,000 |
| Net Margin | -61.8% | -65.1% | -143.4% |
| EPS | $-3.39 | $-1.26 | $-1.59 |
Company Overview
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Visit WebsiteRating Distribution
Strong Buy
1
14%
Buy / Outperform
6
86%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$29
Average Target
↑ 38.8% Upside
Now
$19
Low
$29
Average
$32
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Raymond James | Initiation | Strong Buy | $19 |
| June 24th 2025 | BTIG Research | Initiation | Buy | $30 |
| April 4th 2025 | Ladenburg Thalmann | Initiation | Buy | $32 |
| November 5th 2024 | BofA Securities | Initiation | Buy | $32 |
| November 5th 2024 | Canaccord Genuity | Initiation | Buy | $30 |
| November 5th 2024 | JP Morgan | Initiation | Overweight | $32 |
| November 5th 2024 | TD Cowen | Initiation | Buy | $31 |
| November 5th 2024 | William Blair | Initiation | Outperform | - |
Earnings History & Surprises
CBLLBeat Rate
60%
Last 5 quarters
Avg Surprise
-23.1%
EPS vs Estimate
Beats / Misses
3/2
Last 12 quarters
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q4 24
No data
Q4 24
-125.6%
$-1.85vs$-0.82
Q1 25
-25.0%
$-0.40vs$-0.32
Q2 25
+16.3%
$-0.36vs$-0.43
Q3 25
+5.0%
$-0.38vs$-0.40
Q4 25
+14.0%
$-0.37vs$-0.43
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.43 | $-0.37 | +14.0% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.32 | $-0.40 | -25.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.82 | $-1.85 | -125.6% | ✗ MISS |
Q4 2024 | Oct 11, 2024 | — | $-1.59 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-1.59 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.35 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.30 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-1.35 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-1.35 | — | — |
Latest News
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $30
📈 PositiveBenzinga•Dec 17, 2025, 07:55 PM•Also:
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
📈 PositiveBenzinga•Dec 15, 2025, 10:39 AM
CeriBell shares are trading higher after the company announced it received FDA 510(k) clearance for its proprietary delirium monitoring solution.
📈 PositiveBenzinga•Dec 9, 2025, 02:18 PM
Ceribell Receives FDA 510(k) Clearance For Delirium Monitoring Solution
📈 PositiveBenzinga•Dec 9, 2025, 01:04 PM
CeriBell's Clarity Algorithm Gets FDA's Clearance To Detect Electrographic Seizures In Newborns Pre-Term, Older
📈 PositiveBenzinga•Nov 24, 2025, 01:03 PM
JP Morgan Maintains Overweight on CeriBell, Lowers Price Target to $17
➖ NeutralBenzinga•Nov 5, 2025, 07:52 PM
TD Cowen Maintains Buy on CeriBell, Lowers Price Target to $20
📈 PositiveBenzinga•Nov 5, 2025, 06:43 PM
CeriBell Files For Mixed Shelf Of Up To $300M
➖ NeutralBenzinga•Nov 4, 2025, 10:28 PM
CeriBell Raises FY2025 Sales Guidance from $85.000M-$88.000M to $87.000M-$89.000M vs $86.940M Est
📈 PositiveBenzinga•Nov 4, 2025, 09:12 PM
CeriBell Q3 EPS $(0.37) Beats $(0.41) Estimate, Sales $22.589M Beat $21.779M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:12 PM
CeriBell shares are trading higher. Raymond James initiated coverage on the stock with a Strong Buy rating and a price target of $19.
📈 PositiveBenzinga•Oct 21, 2025, 06:23 PM
Raymond James Initiates Coverage On CeriBell with Strong Buy Rating, Announces Price Target of $19
📈 PositiveBenzinga•Oct 21, 2025, 05:39 PM
Frequently Asked Questions about CBLL
What is CBLL's current stock price?
CeriBell, Inc. (CBLL) is currently trading at $21.20 per share. The stock has moved -0.70% today.
What is the analyst price target for CBLL?
The average analyst price target for CBLL is $30.00, based on 1 analyst.
What sector is CeriBell, Inc. in?
CeriBell, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is CBLL's market cap?
CeriBell, Inc. has a market capitalization of $0.79 billion, making it a small-cap company.
Does CBLL pay dividends?
No, CeriBell, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BFLY
Butterfly Network, Inc.
$3.56
Mkt Cap: $0.9B
EHAB
Enhabit, Inc.
$9.56
Mkt Cap: $0.5B
KIDS
OrthoPediatrics Corp.
$17.07
Mkt Cap: $0.4B
LAB
Standard BioTools Inc.
$1.63
Mkt Cap: $0.6B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
SMLR
Semler Scientific, Inc.
$17.93
Mkt Cap: $0.3B
SRDX
Surmodics, Inc.
$42.98
Mkt Cap: $0.6B
TMCI
Treace Medical Concepts, Inc.
$2.57
Mkt Cap: $0.2B
VREX
Varex Imaging Corporation
$12.29
Mkt Cap: $0.5B
Explore stocks similar to CBLL for comparison